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As a link between inflammation and cancer has been reported in many studies, we established an in vitro model of
prostatic inflammation to investigate the loss of androgen receptor (AR)-mediated signaling in androgen responsive
prostate cell lines. First, the U937 monocyte cell line was differentiated into macrophages using phorbol acetate
(PMA), and cells were induced with lipopolysaccharide (LPS) for cytokine secretion. Next, the cytokine levels (TNFa, IL-
6, and IL1b) in conditioned media (CM) were analyzed. Prostate cells were then fed with CM containing varying
concentrations of TNFa, and IkB degradation, nuclear factor kappa B (NFkB) translocation and transactivation, and the
expression of matrix metalloproteinase-8 (MMP8) and matrix metalloproteinase-9 (MMP9) were then assessed. As a
result of CM treatment, ubiquitin-mediated AR degradation, which was restored using anti-TNFa antibody neutraliza-
tion, led to both a decrease in KLK4, PSA, and NKX3.1 expression levels and the upregulation of GPX2. In addition to
the loss of AR, acute and chronic CM exposure resulted in p53 degradation and consequent p21 downregulation,
which was also restored by either androgen administration or ectopic NKX3.1 expression via the stabilization of
MDM2 levels in LNCaP cells. Additionally, CM treatment enhanced H2AX(S139) phosphorylation (a hallmark of DNA
damage) and genetic heterogeneity in the absence of androgens in prostate cells without activating mitochondrial
apoptosis. Thus, the data suggest that inflammatory cytokine exposure results in the loss of AR and p53 signaling in
prostate cells and facilitates genetic heterogeneity via ROS accumulation to promote prostate carcinogenesis.
 2012 Wiley Periodicals, Inc.
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INTRODUCTION
The secretion of inflammatory cytokines and the
expression of nuclear factor kappa B (NFkB) and sig-
nal transducers and activators of transcription 3
(STAT3) have been shown to contribute to inflam-
mation-induced cancers by mediating the ROS-
associated effects within cells [1]. Many cytokines
and growth factors generate reactive oxygen species
(ROS) via the activation of locally recruited NADPH
oxidases [2]. ROS plays a substantial role in multiple
signal transduction pathways, including the TNFa
pathway [3], and is generated in excess amounts
during chronic inflammation. It is recognized that
elevated ROS levels that are sustained for extended
periods of time may induce DNA damage [4,5]. This
DNA damage includes point mutations in cancer-
associated genes and may result in the genetic alter-
ation of essential cellular proteins involved in
DNA repair, apoptosis, and cell cycle regulatory
mechanisms [6]. Therefore, the appropriate cellular
response to ROS production represents a critical
event. Preventing cells from further oxidative
damage is required to maintain cell survival by elim-
inating the damaged cells and might be advantages
for multicellular organism. Although, NFkB some-
times contributes to cell death, ROS modulates the
NFkB response and results in the activation of NFkB-
mediated transcription that upregulates certain tar-
get genes that ease the expression of additional ROS
production to promote cell survival [7]. Neverthe-
less, in prostate tissue, age-dependent factors such
Additional supporting information may be found in the online
version of this article.
Lokman Varisli present address is Faculty of Science, Department
of Biology, Osmanbey Campus, Harran University, Sanliurfa, Turkey.
Syed Muhammad Hamid present address is Faculty of Science,
Department of Molecular Biology, Izmir Institute of Technology,
Gulbahce, Izmir, Turkey.
*Correspondence to: Cancer Biology Laboratory, Department of
Bioengineering, Ege University, Bornova, Izmir, Turkey.
Received 12 May 2012; Revised 5 July 2012; Accepted 24 July
2012
DOI 10.1002/mc.21948
Published online 21 August 2012 in Wiley Online Library
(wileyonlinelibrary.com).
 2012 WILEY PERIODICALS, INC.
as diminished AR and p53 activity may function
mutually with the aforementioned mediators, and
therefore, inflammation-mediated carcinogenesis
may negatively influence prostate cell maintenance
[8,9]. For this reason, molecular effects, such as
functional AR transactivation and growth control,
require detailed examination under inflammatory
conditions.
In the presence of androgens, AR-mediated tran-
scription regulates the expression of prostate main-
tenance factors and oxidative stress regulators, such
as antioxidant enzymes and ROS scavengers [10]. It
is well recognized that the loss of AR activity con-
tributes to cell survival in two ways. First, the loss of
AR activity results in elevated kinase activity and
the expression of calcium/calmodulin-dependent ki-
nase II (CaMKII), which leads to the growth of an-
drogen-independent prostate cells via the activation
of the anti-apoptotic PI3K/Akt pathway [11]. Sec-
ond, apoptosis is weakly triggered by p53 in the ab-
sence of the AR in prostate cells even when they are
exposed to genotoxic agents, such as doxorubicin
and camptothecin [12]. Ouyang et al. [13] have de-
scribed one putative mechanism for the cancer initi-
ating phenotype in the prostate in which genes
such as glutathione peroxidase 2 (Gpx2), glutathione
peroxidase 3 (Gpx3), peroxiredoxin 6 (Prdx6), and
sulfhydryl oxidase Q6 (Qscn6) were found to be
deregulated in NKX3.1 tumor suppressor mutant
mice in comparison with wild type mice. These
results suggest that the AR target gene, NKX3.1, sup-
presses cancer initiation by protecting the cell
against oxidative damage by regulating the tran-
scription of both pro- and antioxidant enzyme
encoding genes. Therefore, the loss of NKX3.1 due
to proteasomal degradation induced by inflammato-
ry cytokines such as TNFa and IL-1b [14] might be
strongly linked with inflammation induced tumori-
genesis, and implies that this might provide an irre-
versible growth advantage at the first steps of
prostate carcinogenesis [14].
NKX3.1 is an androgen responsive gene and it is
upregulated in the presence of androgens expressed
at levels 8- to 10-fold greater than basal levels [15–
17]. We hypothesize that a decrease in the expres-
sion of AR target genes such as KLK4, PSA, and
NKX3.1 might be reduced in association with in-
flammation, which may cause the prolonged activa-
tion of redox-sensitive transcription factors, such as
NFkB. Thus, these events may initiate an inflamma-
tory cascade, in which it requires the mediation of
sustained oxidative damage by related mechanisms,
such as the regulation of NKX3.1 expression, within
the prostate cells.
Overall, our study aims to establish an in vitro
prostatic inflammation model using prostate cells to
study the molecular alterations associated with the
inflammatory microenvironment, such as the gener-
ation of reactive oxygen species, NFkB activation,
uncontrolled proliferation and the increased genetic
heterogeneity due to p53 loss, and both the andro-
gen receptor (AR)- and abrogated AR-mediated ex-
pression of NKX3.1. Therefore, we investigated the
inflammatory microenvironment associated with tu-
morigenic alterations using LNCaP (tumor derived)
and RWPE-1 (immortalized epithelial) prostate cells
for acute (500 pg/ml TNFa, up to 24 h) and chronic
(62 pg/ml and 125 pg/ml TNFa, for 4 wk) CM treat-
ments and analyzed the transcription levels of pro-
liferation- and apoptosis-associated genes during
inflammation using PCR arrays.
MATERIALS AND METHODS
Macrophage Differentiation and Conditioned Media (CM)
Collection
The U937 monocyte cell line was cultured in
RPMI 1640 medium with 10% FBS (fetal bovine
serum) at 378C with 5% CO2. To achieve macro-
phage differentiation and cytokine production, cells
(8  106) were grown in 75 cm2 culture flasks for
2 h prior to treatment. Next, PMA was added at a
final concentration of 2, 4, 8, and 16 nM for 16 h,
and adherent clusters were followed. Cells were
washed twice, and 20 ml of fresh medium was then
added. After allowing the cells to rest for 2–3 h, lipo-
polysaccharide (LPS) was added (10 ng/ml), and the
cells were incubated for 24 h. Finally, the superna-
tant (conditioned medium—CM) was collected and
filtered (0.2 mm) for further use.
Measurement of Cytokines in CM
Before feeding the LNCaP cells with CM, TNFa
(Invitrogen, Carlsbad, CA), interleukin-6 (IL-6) and
interleukin-1beta (IL-1b; Boster Biological Technolo-
gy Co., Fremont, CA) levels were assessed using an
ELISA assay according to the manufacturer’s recom-
mendations. As the exposure is a major component
in our inflammation model, the time (0, 2, 4, 6, 12,
and 24 h) and dose (62.5, 125, 250, and 500 pg/ml
TNFa containing CM) courses of the CM treatment
were optimized. Finally, the TNFa concentration
was selected as a measure of the CM treatment and
is given as a normalized TNFa concentration in the
Results Section.
Cell Culture and Treatments
The LNCaP and RWPE-1 cells were obtained from
American Type Culture Collection (ATCC Manassas,
VA). LNCaP cells were propagated using RPMI 1640
supplemented with 10% FBS, L-glutamine (2 mM),
penicillin (100 U/ml), and streptomycin (100 mg/
ml), while RWPE-1 cells were propagated in Kerati-
nocyte growth medium supplemented with Bovine
pituitary extract and 5 mM EGF at 378C with 5%
CO2. N-acetyl-L-cysteine (L-NAC; 10 mM), wortman-
nin (200 nM), and TBCA (200 nM) treatments were
performed for 1 h prior to cell incubation both with
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and without CM (500 pg/ml TNFa) for 6 and 24 h.
For chronic inflammation, cells were fed with 62
and 125 pg/ml TNFa containing CM for 4 wk. The
concentrations were adjusted by diluting the CM
using RPMI 1640 medium. R1881 (10 nM) treat-
ments were performed 24 h prior to CM treatments
and kept together until harvesting.
Transfections
The NKX3.1 open reading frame (ORF) was ampli-
fied using the following primers: primer F, GGAT-
CCATGCTCAGGGTTCCGGAGCCG and primer R,
GAATTCGGTTGTCACCTGAGCTGGCATTA and sub-
sequently cloned into a pcDNA4/HisMax-TOPO
(Invitrogen) vector according to the manufacturer’s
recommendations. Transfections were performed
using FuGENE HD transfection reagent (Roche,
Mannheim, Germany) for 24 h. Briefly, 4  105 cells
were seeded in 6-cm plates and were propagated the
next day with serum-free medium. The mix was pre-
pared by adding 3 ml transfection reagent into
100 ml serum-free medium and incubating for 5 min
at RT, 1 mg DNA was then added to the mix and
incubated for 15 min. The mix was applied to the
cells dropwise. After 6 h of incubation, fresh RPMI
medium containing 2 FBS and antibiotics was
added to the cells and incubated for an additional
18–42 h.
Measurement of Reactive Oxygen Species Using DCFH
LNCaP cells (105) were seeded in 6-cm plates. The
treatments were performed as described above, and
the cells were collected into 15 ml Falcon tubes
using trypsin-EDTA. The tubes were centrifuged at
200g for 5 min, and the pelleted cells were washed
and resuspended in PBS. The cells were incubated
with DCFH-DA (20 70- dichlorodihydrofluorescein
diacetate, Sigma, UK; 10 mM) for 20 min at 378C.
After incubation, the cells were washed and re-
suspended in PBS and the cells were analyzed imme-
diately using a FacsAria I flow cytometer (BD
Biosciences, San Diego) within the FITC channel.
Antibodies
The antibodies were purchased from the manufac-
turers as follows: the NFkB (p65), p-NFkB (p-p65),
IkB, MMP9, p53, caspase-3, and MDM2 antibodies
were purchased from Cell Signaling, Inc., Danvers,
MA; the gH2AX(S139) and AR antibodies were obtain-
ed from Millipore, USA; the MMP8, Ubiquitin, PSA,
p21, PARP1, pH3(S10), cytochrome C, pAKT(S473), and
NKX3.1 (T19X) antibodies were obtained from Santa
Cruz, Inc., Santa Cruz, CA; and the GAPDH anti-
body was purchased from Ambion, USA. Dr. F. Saat-
cioglu, University of Oslo, provided the NKX3.1
custom antibody. The HRP-anti-mouse and HRP-
anti-rabbit secondary antibodies were purchased
from Amersham, UK and used as recommended.
Cell Lysis, Protein Extraction, and Blotting
For protein extraction, cells were grown in 6-cm
plates (Sarstedt, Nu¨mbrecht, Germany) and washed
once with PBS prior to cell lysis. Next, 250 ml ice-
cold modified RIPA buffer (10 mM Tris Cl (pH 8.0),
1% Triton X-100, 0.1% SDS, 0.1% Na deoxycholate,
1 mM EDTA, 1 mM EGTA, and 140 mM NaCl) con-
taining both protease and phosphatase inhibitors
was added to the plates, and the cells were then
collected into eppendorf tubes using a cell scraper.
The lysates were sonicated for 20 s (25% power,
0.5 cycles), centrifuged at 12,000g for 10 min at 48C,
and the cleared supernatants were transferred into
new tubes. The protein concentration was deter-
mined using a BCA assay (Sigma). Western blots
were performed under standard conditions using
50 mg of protein lysate per lane. First, the proteins
were separated on a 10–12% SDS–PAGE gel and
transferred to a PVDF membrane (Amersham, UK)
using a wet transfer blotter. The PVDF membrane
was blocked with 5% dry milk in TBS-T (Tris-Borate-
Saline solution containing 0.1% Tween 20), and
then primary and secondary antibody incubations
were performed using TBS-T containing 0.5% dry
milk or 5% BSA at RT for 1 h or at 48C overnight.
The membranes were developed using ECL plus
reagent (Amersham, UK) for 5 min and were photo-
graphed using Kodak X-Ray films in a dark room.
Immunoprecipitation
Protein lysates (500 mg) were subjected to immu-
noprecipitation using 2 mg NKX3.1 or AR antibody
at 48C overnight. The antigen–antibody complexes
were collected after incubation with 20 ml Protein
A/G plus agarose (Santa Cruz, Inc.) for 1 h at 48C.
After centrifugation at 4,000g for 5 min, the pellets
were washed with 500 ml modified RIPA buffer five
times. The collected beads were resuspended in
20 ml RIPA buffer, and one half of each sample was
used for the SDS–PAGE run.
WST1 Proliferation Assay
LNCaP (5  103) cells were seeded and grown in
96-well plates for various time points. At the end of
each treatment, WST1 (1:10 final dilution) cell pro-
liferation reagent (Roche Cat No:05015944001) was
added to the cells, and the cells were incubated
for an additional 3 h. At the end of the incubation,
an absorbance at 450 and 690 nm reference wave-
lengths were used to measure the optical density to
calculate the growth rate.
Flow Cytometry and Analysis
The cell cycle distribution was analyzed via flow
cytometry with a FACSCanto (BD Biosciences) and
the FacsDiva 5.0.3 analysis software. Briefly, the cells
were resuspended in PBS and fixed with 100% etha-
nol (cold) applied in a dropwise manner. RNase
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(20 mg/ml) treatment for 30 min at 378C was
followed by propidium iodide (100 mg/ml) staining
1 h at RT. After analysis, the cell cycle phases were
plotted as histograms (mean values).
Total RNA Isolation and cDNA Preparation
Total RNA was isolated from cultured LNCaP cells
using an RNeasy kit (Qiagen, CA), and the yield
was calculated using absorbance readings at 260/
280 nm. Additionally, cDNA synthesis was per-
formed using an RT2 First Strand cDNA Kit (SABio-
sciences, Valencia, CA) for the PCR array and an
Omniscript RT Kit (Qiagen, CA) for other RT-PCR
experiments as recommended by the manufacturers.
Real Time PCR
To examine the gene expression levels; quantita-
tive RT-PCR was performed using a SYBR Green PCR
kit and the LC480 PCR system (Roche). The relative
abundance of each transcript was calculated using a
comparative cycle of threshold (CT) method with
GAPDH as an invariant control. The primers utilized
include NKX3.1 forward: TCTATCAGCATCTGACA-
GGTGAA, NKX3.1 reverse: AGCAGGGTTTGTTATG-
CATGTAG, PSA forward: GCAGAGTGACATGTG-
CTGGA, PSA reverse: CTTGGCTCACAGCCTTCT,
KLK4 forward: CTCGCTAACGACCTCATGCT, KLK4
reverse: CAGCACGGTAGGCATTCTG, GPX2 for-
ward: CAGTCTCAAGTATGTCCGT, GPX2 reverse:
AGGCTCAATGTTGATGGT, GAPDH forward: CATT-
GCCCTCAACGACCACTTT, and GAPDH reverse:
GGTGGTCCAGGGGTCTTACTCC.
Gene Expression Array
A 96-well PCR array (SABiosciences, Inc., cat. no.:
PAHS065) was used to analyze the gene expression
profile of CM-treated cells (2, 4, and 24 h) compared
with controls. Briefly, cDNA (50 ng/well) was pre-
pared from samples, added to the RT2 SYBR Green
Master mix and distributed into the wells. The PCR
reactions were performed according to the manufac-
turer’s recommendations, and the results were ana-
lyzed using the comparative cycle of threshold (CT)
method with four different genes (B2M, HPRT1,
RPL13A, and GAPDH) as invariant controls.
CM Neutralization
Polyclonal TNF-a antibody (2 mg; Cell signaling)
was added to either RPMI 1640 medium or CM
(containing 500 pg/ml TNF-a) and incubated at 48C
overnight with rotation. The cells were then treated
with either neutralized or control medium for
6 h. Immunoblot analysis of the NKX3.1, AR and
GAPDH expression levels was performed using
specific antibodies.
NFkB Luciferase Reporter Assay
Cells (5  105) were seeded in 6-cm culture plates.
Negative and positive control vectors (100 ng/ml),
and NFkB (100 and 250 ng/ml) reporter (Cignal
Reporter Assay kit, SABiosciences) were transfected
as described above for 24 h. Next, the cells were
treated with CM for 4 h, and then washed with PBS
and collected with passive lysis buffer. To measure
luciferase activity, a dual-luciferase reporter assay kit
(Promega, Mannheim, Germany) was used accord-
ing to manufacturer’s protocol.
Nuclear-Cytoplasmic Fractionation
The cells were rinsed, scraped into cold PBS and
then centrifuged at 300g for 5 min. The pellets were
suspended in 500 ml buffer A (50 mM HEPES pH 7.4,
10 mM KCl, 1 mM EDTA, 1 mM EGTA, and 1 mM
DDT; supplemented with protease and phosphatase
inhibitors) and incubated on a rotator for 30 min.
Next, the samples were centrifuged at 4,000g for
30 min, and the supernatant (cytoplasmic extract)
was collected. The cell pellet was washed four times
with buffer A and centrifuged again at 4,000g for
5 min. After washing, the pellet was resuspended in
500 ml buffer B (50 mM HEPES pH 7.4, 1 mM EDTA,
1 mM EGTA, 400 mM KCl, and 0.5% Triton X-100;
supplemented with protease and phosphatase inhib-
itors) and incubated on a rotator for 30 min. Centri-
fugation was performed at 14,000 g for 30 min, and
the supernatant (nuclear extract) was collected. All
incubations and centrifugations were performed at
48C.
Statistics
The Student’s t-test was applied to assess the sta-
tistical significance between pairs when necessary.
RESULTS
To examine whether macrophage infiltration dur-
ing inflammation is associated with prostate cancer,
we established a model to investigate the involve-
ment of inflammation-mediated cytokines in pros-
tate carcinogenesis [6,9,18]. To verify the model, we
examined, first the NFkB activation following condi-
tioned medium (CM) treatment, and second the
ROS mediated effects on cell growth upon inflam-
mation. Furthermore, we also analyzed the uncon-
trolled proliferation of prostate cells following the
abrogation of AR and p53 signaling upon CM treat-
ment in dose and time course studies.
U937 Cells Differentiate Into Macrophages and Produce
Cytokines
As a sign of macrophage differentiation, U937
cells generate clumps and develop adhesion after
treatment with varying concentrations of phorbol
acetate (PMA) in culture. Therefore, PMA treatment
was used to induce the differentiation of the U937
monocyte cell line into macrophages, and the
clumps were subsequently followed (Figure 1A).
Afterward, differentiated cells were washed and LPS
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(10 ng/ml) was administered to induce cytokine se-
cretion. After 24 h, the conditioned medium (CM)
was collected, filtered, and the cytokine levels were
measured using ELISA assay. TNFa level was found
to be significantly higher (at 510 pg/ml at 16 nM
PMA induction) than the control with PMA only in
U937 cells, while IL1b and IL-6 levels were margin-
ally increased (12.8, and 4.0 pg/ml; Figure 1B–D). As
the induced IL1b and IL-6 concentrations remained
lower than the normal serum levels [19] (TNFa:
12.7, IL-1b: 30.5, and IL-6: 10.3 pg/ml), and also the
basal levels in LNCaP cells (IL1b [30.7  5.7 pg/ml],
IL-6 [17.1  0.3 pg/ml], and TNFa [13.6  3.0 pg/
ml]), the stimulated TNFa concentration (almost
190-fold of control; P < 0.01) was used as a measure
of inflammation strength to adjust the CM concen-
tration for LNCaP cells.
CM Treatment Enhanced MMP9 Expression Mediated by
NFkB Translocation
CM was used to feed LNCaP cells to facilitate a
dose-dependent and controlled inflammatory micro-
environment in cell culture with varying TNFa con-
centrations (62.5, 125, 250, and 500 pg/ml). We
found that LNCaP cells displayed a distinguished
morphology after 3–6 h of CM treatment (Figure 2A),
as the cells had a tendency to form clumps rather
than spreading out. Next, we examined the effect
of the CM exposure time (2, 4, 6, 12, and 24 h)
to determine the highest levels of NFkB phosphory-
lation and IkB degradation in LNCaP cells. Accord-
ingly, CM exposure led to an increase in IkB
degradation beginning at 4 h, thereby resulting in a
consequent a peak level of NFkB(S536) phosphoryla-
tion at 6 h (Figure 2B). We found that the nuclear
translocation of NFkB increased in both cell lines
following CM treatment (Supplementary Figure 1A).
Furthermore, we found that the expression levels
of both the active (p84) and inactive (p92) forms of
the NFkB transcriptional target, MMP9, increased
following 12 h of CM treatment. MMP8 expression
levels were also elevated following the 6 h treat-
ment in our inflammation model. Moreover, using
reporter assay we found that CM treatment induced
NFkB transactivation hundred fold compared
with the control reporter (Figure 2C). Taken to-
gether, these data suggest that NFkB nuclear trans-
location and subsequent transactivation occurs in
prostate cells as an early response to cytokine
exposure.
Figure 1. (A) U937 cells form aggregates upon PMA treatment (2–16 nM for 16 h) and differentiate into
macrophages. These cells produce cytokines after induction with LPS (10 ng/ml). Secreted cytokines levels
are presented. (B) IL1B, (C) IL-6, and (D) The TNFa secreted from differentiated cells was measured via ELISA,
and the concentrations are given in histogram plots. The measurements were performed for every individual
experiment and were reproducible. The error bars show the standard deviations (SD) for each cytokine
concentration.
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ROS-Mediated Proliferation Is Suppressed by the
Antioxidant L-NAC
Many cytokines and growth factors generate ROS
as signaling secondary messengers [2]. This property
contributes to the progression of cancer by adding
further DNA alterations to the genome of a cell pop-
ulation during inflammation. Therefore, intracellu-
lar ROS levels were examined in dose and time-
course studies in this report. We found that the ROS
levels correlated with increasing TNFa concentra-
tions, which can be significantly abrogated using
the antioxidant L-NAC in LNCaP cells (Figure 2D,E).
Cell growth was analyzed using WST assay, and we
found that the proliferation rate increased with CM
treatments at 62.5 and 125 pg/ml, whereas the pro-
liferation rate decreased with CM treatments con-
taining 250 pg/ml TNFa and at higher TNFa
concentrations (Figure 2F). Overall, the data suggest
that the cells respond to cytokines differently above
physiological doses longer than 12 h of exposure.
CM Treatment Results in the Upregulation of Proliferation-
Associated Genes
Based on the gene expression analysis performed
following the 2, 4, and 24 h CM treatments, con-
siderable alterations in the expression levels of
antioxidant defense genes were observed. Not sur-
prisingly, a significant (P < 0.05) upregulation of
PXDNL, MBL2, MPO, PTGS1, and NCF1 was ob-
served, while SEPP1 was found to be downregulated,
which depended on the CM concentration and was
consistent with the levels of NFkB activation
(Figure 3A). These expression data confirm that the
response is generated due to in vitro inflammation
in prostate cells. Furthermore, the expression of
the antioxidant defense genes aldehyde oxidase 1
(AOX1), diacylglycerol kinase kappa (DGKK), gluta-
thione peroxidase 3 (GPX3) and glutathione peroxi-
dase 7 (GPX7) were also found to be upregulated in
LNCaP cells following CM treatment in comparison
with controls (Figure 3B). As the time-dependent
changes are consistent, we demonstrated that CM
exposure enhanced keratin 1 (KRT1) expression at
more than 200-fold that of the control in 4 h
(Figure 3C). Moreover, prostaglandin–endoperoxide
synthase 2 (PTGS2) expression levels were also in-
creased up to 60-fold compared with the control at
following the 24 h CM treatment. The expression
levels of tumor differentiation related factor dual
oxidase 2 (DUOX2) [20], lung adenocarcinoma pro-
liferation and migration promoting factor apolipo-
protein E (APOE) and the tumor growth driving
peroxide, glutathione peroxidase 2 (GPX2) [21,22],
Figure 2. (A) Morphological alterations were observed in prostate
cells when LNCaP cells were treated with conditioned media
(500 pg/ml TNFa) for 6 h (magnification 10). (B) NFkB signaling
was activated by CM, as presented here in a time course study
assessed by Western blot. An increased expression of MMP9 was
observed as a result of IkB degradation and NFkB transactivation.
Additionally, activation of the innate immune response led to an in-
crease in MMP8 expression. GAPDH expression levels are shown to
demonstrate the equal loading of lysates. (C) NFkB activity increased
upon CM treatment for 4 h, as shown using a NFkB reporter assay.
(D) The intracellular ROS levels increased in time with CM treatment
(500 pg/ml TNFa), (E) the intracellular ROS levels increased with in-
creasing TNFa concentrations (62, 125, 250, and 500 pg/ml) in
LNCaP cells. The treatments were performed in the presence or ab-
sence of antioxidant L-NAC for 2 h and were measured using DCFH
dye via flow cytometer. (F) The increasing doses of TNFa containing
CM influenced the proliferation of LNCaP cells, as shown in the pres-
ence or absence of L-NAC for 24 h.
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were also increased by CM treatment. As MT-3 and
SEPP1 were downregulated by CM treatment, the
deregulated expression of the antioxidant defense
genes described above could be associated with
cell growth and proliferation and are significantly
altered upon CM exposure (Figure 3C). Taken to-
gether, our in vitro prostate inflammation model
mimics the inflammation-mediated changes in gene
expression.
Blocking Kinases Restores the CM-Mediated Loss of AR but
not AR-Mediated Transactivation
A number of cellular processes control the growth
and survival of prostate cancer cells to regulate the
expression, stability and function of the AR and pos-
sibly circumvents the androgen requirement for AR
transactivation [23,24]. Here, we examined the loss
of the AR-mediated signaling during CM treatment
via time course studies (0, 2, 4, 6, 12, and 24 h) in
prostate cells (Figure 4 and Supplementary Figure 1).
AR and androgen responsive NKX3.1 expression lev-
els were found to be reduced at 6 h (Figure 4A–C)
with a complete loss at 12–24 h (Figure 4E,F) of CM
exposure in LNCaP cells regardless of androgen,
whereas only AR loss was evident in RWPE-1 cells
(Supplementary Figure 1B). As these losses may be
either transcriptional or associated with proteasomal
degradation, the ubiquitination of both the AR
and NKX3.1 was assessed in our studies. Thus, the
highest levels of ubiquitination was observed with
the 6 h of CM treatment, AR expression level was
also found lower than that of the control cells
(Figure 4A). Taken together, prostate cells rely on
both androgens and the AR for controlled mainte-
nance and survival; the data suggest that the treat-
ment with CM containing high doses of TNFa
(500 pg/ml) contributes to the loss of AR signaling
even at short exposures in acute inflammation
model.
Furthermore, to investigate if the CM-mediated
AR degradation can be suppressed, LNCaP cells were
treated with Akt and CK2 kinase inhibitors (wort-
mannin and TBCA, respectively) in addition to CM
treatments. Then, we found that both inhibitors
partially restored the CM-mediated degradation
of the AR at shorter exposures in the absence of
Figure 3. The expression levels of oxidative stress and antioxidant defense genes are shown after the treat-
ment of LNCaP cells with CM (2, 4, and 24 h). The inflammation response (A), antioxidant defense (B), and
the genes contributing to proliferation and/or tumorigenesis (C) are displayed here. PCR array studies were
performed three times and P values were calculated (<0.05). The error bars represent the SD for each histogram
plot.
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androgen (Figure 4B,C). Accordingly, AR-mediated
transactivation was also verified with the analysis of
PSA expression (compared with GAPDH expression
levels) following CM treatment (Figure 4B,C) in the
presence of androgens (R1881), and found that the
use of wortmannin restored the AR expression, but
not PSA expression. When PSA, KLK4, and NKX3.1
mRNA expressions were examined, it was found
that CM treatment downregulated the expressions
at 24 h (Figure 4D). As the specific CK2 and Akt
inhibitors restored the degradation of the AR but
not the transactivation, these results suggest that in-
flammation-mediated AR signaling is abrogated
even at very short CM exposures. Further, the CM
exposure time was extended to 24 h and observed
that the use of kinase inhibitor wortmannin could
not sustain the inhibitory effect on AR and NKX3.1
degradation (Figure 4E,F), implied that this can be
related to short half-life of wortmannin in cell
culture.
AR Degradation Is Mediated by TNFa
To validate the TNFa-mediated effects, the degra-
dation of AR and NKX3.1 was neutralized using
TNFa specific polyclonal antibody, and the restora-
tion of expression was examined. Intriguingly,
consistent with the results in kinase inhibitors
(Figure 4), TNFa antibody treatment restored the AR
expression (Supplementary Figure 2A, lanes 3 and 4)
over the basal levels in controls (lanes 1 and 2) re-
gardless of CM treatment. Furthermore, recTNFa in-
duction was performed in LNCaP cells for 3, 6, and
24 h, and immediate loss of NKX3.1 and degrada-
tion of AR were also observed. As, the initial in-
crease in AR expression evolved into a significant
decrease at longer exposures demonstrates that AR
Figure 4. (A) The ubiquitination of AR and NKX3.1 are shown. (B)
LNCaP cells were treated with wortmannin (200 nM) for 7 h (added
onto cells 1 h prior to conditioned media) in the presence or absence
of R1881 (10 nM) and CM (500 pg/ml TNFa) for 6 h. The AR,
NKX3.1, and PSA expression levels and the AKT(S473) phosphorylation
level are displayed. (C) LNCaP cells were treated with 200 nM TBCA
for 7 h in the presence or absence of R1881 (10 nM) and CM
(500 pg/ml TNFa) for 6 h. The PSA and NKX3.1 expression levels
were given the loss of AR transactivation function. (D) AR-mediated
transcription (PSA, KLK4, and NKX3.1 transcription levels) was
downregulated by 24 h CM exposure as assessed by RT-PCR. GPX2
expression was also assessed as a non AR-mediated expression con-
trol. LNCaP cells were treated with either wortmannin (200 nM; E)
or TBCA (200 nM; F) for 25 h (added onto cells 1 h prior to CM) in
the presence or absence of R1881 (10 nM) and CM (500 pg/ml
TNFa) for 24 h. The AR and NKX3.1 expression levels are shown.
Western blots were performed at least three times.
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and NKX3.1 degradations are mediated by TNFa
in prostate cells, and the loss of expression is likely
independent from AR transcriptional control.
Chronic Exposure to CM Contributes to the Loss of p53
Transactivation
During CM exposure in the time course studies (0,
2, 4, 6, 12, and 24 h), a marginal MDM2 stabiliza-
tion was observed at the p90 level without an alter-
ation in the p60 levels (degradation of MDM2;
Figure 5A). This subsequently resulted in a decrease
in both p53 and p21 expression levels. However,
cell cycle analysis results using ModFit [25] showed
that there was no change until the 6 h of CM treat-
ment, whereas the G1 population increased with
the 12 and 24 h treatments (Figure 5B and
Supplementary Figure 3). These data suggest that
the loss of p21 function at G1 arrest is mediated by
p53 and facilitated by AR signaling, which were ab-
rogated by CM treatment in LNCaP cells. Addition-
ally, the loss of p53 expression contributed to an
increase in DNA damage, which was demonstrated
by an increase in H2AX phosphorylation, while cy-
tochrome C levels remained unchanged (Figure 5C).
However, the administration of androgen (R1881)
led to an increase in the degradation of MDM2
(p60), regardless of the CM treatment, and main-
tained p53 stabilization in LNCaP cells. As the high
concentration of CM treatment was performed for
6 h, the partial restoration of p53 by androgen
administration was confirmed by assessing the p21
expression levels (Figure 5D). Ectopic NKX3.1
Figure 5. (A) MDM2 p90 expression levels increased with the con-
current loss of p53. The subsequent downregulation of p21 is shown
following CM treatment of 6 h or more. (B) Cell cycle phases are
displayed via histogram. The number of cells in the G1 phase in-
creased after 6 h, while the cell count in the S phase decreased by
increasing the exposure time. (C) Inflammation contributes to DNA
damage by enhancing H2AX(S139) phosphorylation in a time-depen-
dent manner. H3(S10) phosphorylation increased and reached the
peak level at 6 h, while apoptosis was not induced. Cytochrome C
levels remained unchanged, whereas PARP1 and gH2AX(S139) degra-
dation levels increased upon CM exposure. These results show that
DNA damage increases with p53 loss. (D) The loss of p53 following
CM exposure was restored via androgen administration, and NKX3.1
expression (E) subsequently activated p21 transcription. (F) Chronic
inflammation (CM treatment containing 62.5 and 125 pg/ml TNFa
during 4 wk) leads to a decrease in both NKX3.1 and AR protein
levels. Additionally, apoptotic control was abrogated as a result of
p53 protein loss. p21 expression was maintained with 62.5 pg/ml
TNFa/CM; however, it is completely downregulated with 125 pg/ml
TNFa/CM. Ultimately, no changes were observed in caspase-3 cleav-
age. pH3(S10) revealed increased mitosis following 125 pg/ml TNFa/
CM-induced chronic inflammation. (G) The schema summarizes the
mechanism involving MDM2 and p53, which are negatively influ-
enced by the inflammatory microenvironment and restored in the
presence of androgen and NKX3.1 expression.
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expression also restored p53 transactivation during
CM treatment, which was also confirmed with by
the increasing p21 expression levels (Figure 5E).
Thus, androgens restore p53 transactivation and its
growth regulatory function via crosstalk with AR,
and this interaction presumably suppresses the
development of error-prone phenotype in prostate
cells.
As the link in between chronic inflammation and
tumorigenesis has already been established in many
tumors, chronic inflammation was also studied
using LNCaP cells. AR and NKX3.1 loss were ob-
served until 4 wk of CM exposure (CM containing
125 pg/ml TNFa). Accordingly, we found that apo-
ptotic regulation could not be maintained via
decreased p53 levels, which was confirmed with the
unchanged caspase-3 cleavage upon CM exposure.
Furthermore, at lower doses of CM (62 pg/ml
TNFa), p21 expression levels increased, whereas
H3(S10) (mitosis marker) phosphorylations were sig-
nificantly depleted. These data suggest that the cells
arrest and do not proliferate at lower doses of CM
treatment. Consistently, at higher concentrations of
CM, which resulted in an increase in H3(S10) phos-
phorylation levels, the complete loss of p53 and p21
was observed (Figure 5F). Thus, we have shown that
androgen administration partially restored p53 func-
tion and p21 expression levels, while NKX3.1
expression considerably restored p53 function and
p21 expression levels, which were abrogated by
inflammatory cytokines in prostate cells (Figure 5G).
DISCUSSION
Previous reports have demonstrated that the
inflammatory microenvironment contributes to
cancer initiation, which can be facilitated via major
growth regulatory pathways, such as Akt and p53
as well as AR in prostate tissue [4,5]. As both AR
expression and signaling are extensively studied in
prostate cancer, AR is a well-recognized mainte-
nance factor, requires for the regulated growth of
prostate cells [13]. Here, we investigated the mole-
cular alterations that may facilitate prostate carcino-
genesis, and examined these responses by
simulating the inflammatory microenvironment in
vitro [19]. In this study, we have shown that CM
exposure results in a profound increase in the degra-
dation of IkB and subsequent NFkB transactivation
following its nuclear translocation. Therefore, CM
treatment establishes an inflammatory microenvi-
ronment in vitro and the basal cellular phenotype
mimics the initiation of prostate carcinogenesis sub-
sequent of NFkB activation in androgen responsive
LNCaP cells.
To validate the model, a number of antioxidant
genes including the GPX3, GPX7, KRT1, PTGS2,
DUOX2, APOE, MT-3, SEPP1, and NOS2 were ana-
lyzed for expression and found that these factors are
changing in expression in an agreement with previ-
ous studies [26–31]. As the deregulated expressions
of antioxidant defense genes, such as reported
above, are related to the cell growth and prolifera-
tion and is critically altered even at short exposures
of CM treatments (Figure 3), we suggest that our in
vitro inflammation model mimics the prostatic in-
flammatory atrophy (PIA), and the inflammation-
mediated gene expression changes in prostate cells.
Further, the ROS levels were examined and the in-
crease in ROS-mediated cell growth was suppressed
with an antioxidant use. These results also imply
that the ROS-mediated effects can be regulated by a
scavenging mechanism in prostate cells, and this
requires an intact maintenance factor, such as AR,
to facilitate the androgen-regulated factor NKX3.1
expression.
Moreover, in a previous study, Culig et al. [32]
have reported that the AR transactivation function
is abrogated by administration of IL-1b, where the
PSA expression was also found downregulated. Fur-
ther, in another report, Markowski et al. [14] have
also shown that TNFa and IL-1b induced the loss of
NKX3.1 via proteasomal degradation [14]. Since,
these studies have extensively addressed the specific
NKX3.1 phosphorylations and the AR turnover
respectively, in another study, Khalili et al. [33]
have demonstrated that the reduced expression of
NKX3.1 significantly correlates with an increased
expression of the proliferation marker, Ki67, in
infected prostate lobes. In this model, they injected
an uropathogenic Escherichia coli strain into mice
using intraurethral inoculation to establish an
in vivo prostate inflammation model. They also
reported that AR expression was downregulated in
these infected prostate luminal ducts; although, the
expression levels remained detectable in all cases. As
with the Nkx3.1 results, AR protein level was also
retained in non-inflamed ducts adjacent to inflamed
ducts. Since, it was demonstrated that AR expression
was restored in epithelial cells when the inflamma-
tion was cleared [33], the transactivation function
was not examined implied us that the retained ex-
pression of AR and NKX3.1 may not be functional
for both prostate development and maintenance in
infected prostate luminal cells [33]. Hence, the data
in the previous reports strongly correlate with the
CM-mediated AR and NKX3.1 degradation [13],
which are demonstrated here, might be subsequent
to abrogated antioxidant response during inflamma-
tion in a dose and time dependent manner.
The physiological level of TNFa from blood
of healthy donors was reported to be in the range
of 0–67.6 pg/ml [34] and the IL-1b concentration
included in CM remains lower than LNCaP intrinsic
level. Thus, different concentrations of CM (up to
500 pg of TNFa) for 6 and 24 h were used in our
studies. While, it is well known that the macro-
phage infiltration increases cytokine release [34],
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the TNFa concentration is expected to be remark-
ably high in these tissues. However, since a consid-
erable degradation of AR and NKX3.1 was observed
with aforementioned concentrations; therefore,
much lower concentrations of TNFa (62.5, 125, and
250 pg/ml) for longer exposures simulated a chronic
inflammation in our studies. The NKX3.1 degrada-
tion might facilitate the proliferation during the ear-
ly steps of prostate carcinogenesis by deregulating
the expression of antioxidant defense genes. As the
concentrations of recombinant cytokines used in
previous studies were almost 100 times higher than
the doses applied in our model (40 ng/ml for both
TNFa and IL-1b), one can conclude that the very
low TNFa exposure might result in the loss of AR-
mediated transactivation as well as ROS regulatory
function in the cell that might facilitate the prostate
cancer progression during inflammation.
Thus, AR-mediated transactivation is downregu-
lated during inflammatory conditions, which results
in the loss of prostate cell maintenance as an initial
response. As the specific CK2 and Akt inhibitors
may restore the degradation of the AR but not
AR-mediated transactivation in prostate cells, the
findings obtained here suggest that inflammation-
mediated AR signaling is an important event and is
abrogated even at short exposure to inflammatory
cytokines, whereas the transactivation function of
AR may not be restored exclusively by the recovery
of AR expression (Figure 6). This result implies
that other factors mediated by AR signaling may
regulate prostate cell maintenance, which may also
be required to retain AR function in prostate cells.
Additionally, we suggest that ROS induces DNA
damage and facilitates tumor progression by pro-
moting genetic heterogeneity in prostate cells. As
inflammation-mediated ROS contributes to the sur-
vival function of NFkB and alters both the adher-
ence and growth properties of prostate cells, its
overall effect is reduced by the use of the antioxi-
dant, L-NAC, in prostate cells. Thus, inflammation-
mediated ROS generation damages cellular genetic
material and negatively influences prostate cell
maintenance by degrading the major contributors
of cell survival, such as AR, NKX3.1 and p53, in
prostate cells.
Figure 6. AR signaling is significantly altered due to the loss of AR in LNCaP cells following CM treatment.
Akt inhibition restores both the AR expression and AR-mediated transactivation, whereas CK2 inhibition
restores only the AR expression but not transactivation. Alterations are presented in a schema where the ligand
(androgen; R1881) and wortmannin synergize the effect.
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Taken together, macrophage infiltration during
inflammation is an important contributor to pros-
tate carcinogenesis, in which cytokines such as
tumor necrosis factor-a (TNFa) function as pro-
inflammatory cytokine and promotes carcinogenesis
[6],[9],[18]. As a result of the TNFa-mediated induc-
tion of NFkB signaling, the ROS-mediated effects
result in an increase in the growth rate, which is
deregulated by androgen signaling in prostate cells.
However, p53 is also a key factor, as it is degraded
via the MDM2-dependent pathway during the in-
flammation and must be functional to maintain
high genome fidelity in these cells. Therefore, the
abrogated AR and p53 response due to the CM treat-
ments resulted in an increase in genetic heterogene-
ity at the inflammatory regions of prostate, where
the error-prone phenotype develops. This mecha-
nism requires extensive investigation in animal
studies. Here, we report that the in vitro prostate in-
flammation model is a relevant and simple model
that can be used to study molecular alterations, cell
growth, AR-mediated transactivation and prostate
cell maintenance upon inflammation.
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